Scottish biotech TC BioPharm lowers deal size by 40%, adds warrants ahead of $30 million US IPO<blockquote>苏格兰生物技术TC BioPharm将交易规模降低40%,并在3000万美元美国IPO前增加认股权证</blockquote>
TC BioPharm Holdings, a Scottish Phase 2 biotech developing allogeneic gamma-delta T cell therapies,